Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04386226 · ClinicalTrials.gov registry record · NA

An Assessment of the Glyconutrient Ambrotose™ on Immunity, Gut Health, and Safety in Men and Women

A NA study of Healthy, sponsored by University of Memphis.

Completed
Registry status
NA
Development phase
75
Enrollment target
1
Study location

NCT04386226 is a NA study of Healthy that has completed, run by University of Memphis. The registered enrollment target is 75 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04386226, a NA study of Healthy, has completed, sponsored by University of Memphis.

COMPLETED
Registry status
NA
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

This study evaluates the impact of two Ambrotose products on immunity, gut health, and associated measures in healthy men and women. Subjects are randomly assigned in double-blind manner to one of five conditions: 1) 2 grams Advanced Ambrotose, 2) 4 grams Advanced Ambrotose, 3) 2 grams Ambrotose LIFE, 4) 4 grams Ambrotose LIFE, or 5) placebo. Subjects ingested their assigned condition daily for eight weeks.

Conditions Studied

Interventions

  • OTHER Placebo
  • DIETARY_SUPPLEMENT Ambrotose LIFE
  • DIETARY_SUPPLEMENT Advanced Ambrotose

Study Locations (1)

Tennessee

  • Center for Nutraceutical and Dietary Supplement Research - Memphis

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2018-08-15
Est. Completion 2019-06-01
Phase NA

Sponsor

University of Memphis

35 total trials

What the Registry Record Tells You About NCT04386226

The ClinicalTrials.gov registry entry for NCT04386226 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (88% lower). The listed sponsor is University of Memphis, which has 35 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT04386226 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT04386226 about?

NCT04386226 is a clinical study titled "An Assessment of the Glyconutrient Ambrotose™ on Immunity, Gut Health, and Safety in Men and Women". This study evaluates the impact of two Ambrotose products on immunity, gut health, and associated measures in healthy men and women. Subjects are randomly assigned in double-blind manner to one of five conditions: 1) 2 grams Advanced Ambrotose, 2) 4 grams Advanced Ambrotose, 3) 2 grams Ambrotose LIF...

What is the current status of trial NCT04386226?

This trial is currently completed. It is a NA study. The enrollment target is 75 participants. The study started on 2018-08-15. Estimated completion is 2019-06-01.

What conditions does trial NCT04386226 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT04386226?

The interventions under investigation include: Placebo (OTHER), Ambrotose LIFE (DIETARY_SUPPLEMENT), Advanced Ambrotose (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT04386226?

This trial is sponsored by University of Memphis, which has 35 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04386226 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.